Pharmaceutical Research Division, Shionogi Pharmaceutical Research Center, 3-1-1 Futaba-cho, Toyonaka, Osaka561-0825, Japan.
PeptiDream Inc.3-25-23 Tonomachi, Kawasaki-ku, Kawasaki, Kanagawa210-0821, Japan.
J Med Chem. 2022 Aug 11;65(15):10655-10673. doi: 10.1021/acs.jmedchem.2c00919. Epub 2022 Jul 29.
Recent technological innovations have led to the development of methods for the rapid identification of high-affinity macrocyclic peptides for a wide range of targets; however, it is still challenging to achieve the desired activity and membrane permeability at the same time. Here, we propose a novel small molecule lead discovery strategy, ″Peptide-to-Small Molecule″, which is a combination of rapid identification of high-affinity macrocyclic peptides peptide display screening followed by pharmacophore-guided design of small molecules, and demonstrate the applicability using nicotinamide -methyltransferase (NNMT) as a target. Affinity selection by peptide display technology identified macrocyclic peptide that exhibited good enzymatic inhibitory activity but no cell-based activity. Thereafter, a peptide pharmacophore-guided design and further structure-based optimization resulted in highly potent and cell-active small molecule (cell-free IC = 0.0011 μM, cell-based IC = 0.40 μM), indicating that this strategy could be a new option for drug discovery.
最近的技术创新使得快速鉴定针对广泛靶标的高亲和力大环肽的方法得以发展;然而,同时实现所需的活性和膜通透性仍然具有挑战性。在这里,我们提出了一种新的小分子先导发现策略,“肽到小分子”,它是快速鉴定高亲和力大环肽的结合 - 肽展示筛选,然后进行基于药效团的小分子设计,并用烟酰胺 -N-甲基转移酶(NNMT)作为靶标证明了其适用性。肽展示技术的亲和选择鉴定出了大环肽,该肽表现出良好的酶抑制活性,但没有基于细胞的活性。此后,基于肽药效团的设计和进一步的基于结构的优化产生了高活性和细胞活性的小分子(无细胞 IC = 0.0011 μM,基于细胞的 IC = 0.40 μM),表明该策略可能成为药物发现的新选择。